On Tuesday, Eli Lilly And Company (NYSE:LLY) released topline results from the SURMOUNT-1 three-year study (176-week treatment period) evaluating tirzepatide once weekly for long-term weight management and delay in progression to diabetes in adults with pre-diabetes and obesity or overweight.
Tirzepatide is sold as Zepbound for weight and Mounjaro for diabetes.
Also Read: Roche Misses Out On Weight-Loss Blockbuster Drug, Now Playing Catch-Up In Booming Market.
Tirzepatide was evaluated in 1,032 adults who had pre-diabetes at randomization and obesity or overweight for a treatment period of 176 weeks, followed by a 17-week off-treatment period (193 weeks in total).
Results from the SURMOUNT-1 phase 3 study’s primary analysis at 72 weeks in all participants were
